FDA Approves Intersect ENT’s Sinus Implant Delivery System
Menlo Park, California devicemaker Intersect ENT said that the FDA has approved the delivery system for its Propel Mini sinus implant.
The company’s new Straight Delivery System is designed to place the Propel Mini steroid releasing sinus implant in the ethmoid sinus. The implant helps keep the sinus open during delivery of mometasone furoate, a steroid medication used to treat skin conditions.
The sinus implant helps to improve the outcomes of frontal and ethmoid sinus surgery.